See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that is used to treat various bacterial infections. According to the drug's prescribing information, tigecycline is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.

Tigecycline has been shown to be effective against a wide range of gram-positive, gram-negative, and anaerobic bacteria. It is particularly useful for treating infections caused by bacteria that are resistant to other antibiotics.

According to DrugPatentWatch.com, tigecycline is a glycylcycline antibiotic that is chemically related to tetracyclines but has a unique mechanism of action that allows it to overcome tetracycline resistance. Tigecycline inhibits protein synthesis by binding to the 30S ribosomal subunit, which prevents the formation of bacterial peptide chains.

Tigecycline has been shown to be effective against a variety of bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. It is also active against Acinetobacter baumannii, Pseudomonas aeruginosa, and other difficult-to-treat gram-negative bacteria.

In summary, tigecycline is a broad-spectrum antibiotic that is effective against a wide range of bacterial infections, including those caused by drug-resistant bacteria. It is particularly useful for treating complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.

Sources:

1. Wyeth Pharmaceuticals Inc. (2017). TIGECYCLINE [package insert]. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021867s021lbl.pdf>
2. DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>